Skip to main content

Candel Therapeutics, Inc Investor Event Transcript, Nov 10, 2026

Candel Therapeutics, Inc. (CADL)

CADL’s aglatimogene prostate trial achieved its primary endpoint in December 2024; payer research indicates a median price range of $285,000 for three administrations, though the company said that price was not assured. AI summary

Investor Event Transcript 2026-11-10 For: 2026-12-31
Added on November 15, 2026

Conference Transcript - CADL 2026-11-10

Stephen Willie, Analyst — Stifel

Good. All right. I'm Stephen Willie, one of the senior biotech analysts here at Stifel, and glad to have with us as part of the next session, CEO of Kandel Therapeutics, Paul Peter Toc. We're just going to have kind of a casual discussion here. If anyone has a question, feel free to raise your hand. Paul Peter, thanks for your participation. And I'm not sure if you want to start off with any opening statements before we jump into Q&A.

Paul Peter Tak, CEO

So, good morning, everybody. Well, first, thanks for having me. We are in a very interesting phase of the company. I just came back from CITSI, the immuno-oncology meeting, where we had three abstracts that we presented. One of them was a late-breaking abstract based on the PRTKO5 study. We may come back to that. We had new data also in non-sponsored lung cancer where we used a proteomics approach. It was actually awarded the top 150 abstract award. And then we had another abstract about Linosirpaterov, a second investigational medicine, which is also very interesting, that we test in probably the most difficult-to-treat form of cancer, recurrent glioblastoma, where we could show new immunological biomarker data. And we're starting to see a subset of patients that live much longer than you would expect, even in recurrent glioblastoma. That prognosis is extremely unfavorable. So a lot going on. We're very busy. Also, it's a very strong focus on execution. So that's, in a nutshell, some of the recent ideas.

Stephen Willie, Analyst — Stifel

So let's jump into aglatimogene for localized prostate cancer. Maybe we can just start off with the PRTK05 data you just presented at CITSI. I know the mechanism of this drug is pretty unique. I know that trial was intended to do some immune profiling, some biodistribution, some shedding. What can you say about the data that emerged out of that study, specifically on the immune profiling side, and how that kind of strengthens your confidence that this drug is acting in kind of like that multimodal mechanistic way that you believe it to be?

Paul Peter Tak, CEO

Yeah, so the PRTK05 is an experimental medicine phase 2A clinical trial that was requested by the FDA. So the question was really to repeat the old work on biodistribution and setting. In other words, you test in different body compartments over time whether you can still detect the viral gene construct. We had shown in the past that it's all gone within a few months, which you would expect. Because it's replication-defective adenovirus, it cannot replicate. But second, the cells that we infect, we kill, actually, by giving valacyclophir. But the FDA requested, and rightly so, I think, to repeat that experiment with more state-of-the-art. Technology, and it's one figure on the poster that we presented last week at CITC, where we basically reproduced these findings. But then I thought, well, we're going to inject aglatimogen into the prostate of patients with localized intermediate-risk prostate cancer. Let's use this, actually, to take some extra samples to do sophisticated immunological biomarker research. Because the biosamples were not available from the phase 3 clinical trial that delivered on the clinical endpoints, supported by secondary and exploratory endpoints. But we wanted to measure the systemic immune activation after localized delivery of prostate cancer, which is important for multiple reasons. So let's first focus on the findings. The key findings included a very clear increase. In the number of circulating CD8 positive T cells, including CD8 positive, grensine B positive, that means they are cytotoxic, KI67 positive, that means they are proliferating T cells in the blood. And then also a clear increase in the proportion, in the number of effector memory cells and central memory cells, which may explain the durable responses that we've seen after aglatimogen injection. So it supports the notion that aglatimogen is a systemic immunotherapy. That is delivered locally. And we've shown exactly the same already in the past in other solid tumor, tumors like glioblastoma. So we used to have a program for aglatimogen in glioblastoma as well as part of first-line treatment. We discontinued that for portfolio prioritization reasons, but actually we had very interesting data that we published in neuro-oncology that we could show that after aglatimogen delivered to the brain, We see a broadening of the T-cell receptor repertoire associated with improved survival. We also had data at CITC a few days ago that we showed the same in non-small cell lung cancer where we did proteomics and where we also have shown a broadening of this T-cell receptor repertoire, which is explained by the fact that we basically educated T-cells to recognize a whole variety of cancer antigens and cancer neoantigens that are specific for the patient's own tumor. And this explains in lung cancer that we have seen very clear evidence of an abscopal effect. That means improvement not only at the site of the injected tumor, but also an improvement in the uninjected distant metastases. So that's clinical evidence of systemic anti-tumor immunity. And we've shown the same, and that paper will come out shortly in the literature as well. in borderline resectable pancreatic cancer. So it's really an off-the-shelf product that leads to an individualized systemic anti-tumor immune response. So why is that important for prostate cancer? If you think about our target indication, which is newly diagnosed localized prostate cancer, then it's not just that you kill the tumor cells with the initial hit. Of the toxic metabolite that's formed if you give patients valacyclovir after acletymogen, it suggests that we are inducing a new state of immune surveillance. And if patients, for example, have micrometastases, you could imagine that these T-cells that are circulating throughout the body will be able to find these micrometastases and kill them. But also, it opens up the... Opportunity to expand into later stages of prostate cancer in the future at the right time. Let's say after approval, think of oligometastatic prostate cancer. There's a lot of interest in that field and potentially after that in really advanced disease. So you basically cover the whole field per disease indication and don't leave any patient behind.

Stephen Willie, Analyst — Stifel

Okay. Maybe we can talk about the registrational phase three study in localized prostate cancer. I know we've seen a few changes with respect to kind of how this disease is treated since you initiated this study, I think, a long time ago, 15 years ago. You know, things like how risk subgroups are defined, how radiation is deliberate, et cetera. How do you think the phase three data you've generated aligns with current clinical practice, just in terms of relevancy? And How comfortable are you that the data that you've generated to date kind of fits into that current clinical landscape?

Paul Peter Tak, CEO

Yeah, it's a great question. So the patients in our clinical trial have received EBRT, right, external beam radiotherapy, in the context of radical treatment or definitive treatment. So the goal is to eradicate the tumor, and we've shown by focusing on disease-free survival that we achieved that goal. So these patients got EBRT. And initially, they received conventional EBRT. But then at some point, there was a new type of radiotherapy, which is hypofractionated EBRT. So in 2019, we submitted an amendment to the trial to make it possible for patients to receive a moderate hypofractionated EBRT. So first... This hyperfractionated EVRT does not lead to better clinical outcomes. But basically, you give the same overall dose of radiotherapy in fewer sessions, which is more patient-friendly. So therefore, we amended the protocol. The FDA agreed, confirmed, inviting that the spa was still intact. So this is the first potential change in standard of care over time. And we've shown, if you look at our corporate slide deck, that if you do an exploratory subset analysis and you look at the hazard ratio and compare the conventional EBRT group compared to the moderate hyperfractionated EBRT group, then you see that the hazard ratios are smaller than one. This study was not designed from a statistical point of view, statistical power point of view, to look for statistical significance, but if anything, the hazard ratio looked even smaller after hyperfractionated the EBRT. I think that's probably statistical noise, or it's real because you induce maybe more DNA damage in a short period of time. And the toxic metabolite that's formed under the influence of agletymogen, if you give alacyclovir, is a nucleotide analog. That will be incorporated into cells that exhibit DNA damage. So my short answer here would be that we've shown the beneficial effect of aglatimogen versus placebo independent of the specific type of EBRT. The second important point to make is the use of ADT. So, in intermediate-risk prostate cancer, patients could get, in our trial, short-term ADT, which is defined as 46 months of ADT. We left it to the treating physician. I should mention that most of the patients in our trial were enrolled after 2017, 2018. Then for the first time, professional investors came on board and more centers could be opened. They see real acceleration in enrollment. So actually, most of the patients were treated relatively recently in our clinical trial and got standards of care, short-term ADT. I'm focusing now on intermediate-risk prostate cancer, which is 85% of the patients. But then over time, a new classification was introduced that did not exist at the time of protocol development, namely the distinction between intermediate risk favorable disease, where short-term ADT was and is not indicated, and short-term, sorry, intermediate risk unfavorable disease. Where since the initial introduction of this nomenclature, the recommendation was to give them short-term ADT. So again, we left it open to the treating physician, and we had about 50% of the patients in our trial who received short-term ADT, and we could show the benefit. of aglatimogen versus placebo, independent of the use of short-term ADT. Again, if you look in an exploratory way at the different hazard ratios, that all tend to be smaller than one. But now there's a new guideline that came out four weeks ago, NCCN guidelines, which is completely consistent with what we have done in our clinical trial. Because the new change in the guidelines is that now for intermediate-risk, unfavorable disease, the recommendation is to leave it to the shared decision-making between patient and physician whether the patient will get short-term ADT. So it's very much in line with how we designed the protocol, so we think this is completely relevant. And then finally, we have done multiple sensitivity analyses that show consistently, however you look at the data, based on which version of the NCCN guidelines, we see the same differences between agglotimidin versus placebo.

Stephen Willie, Analyst — Stifel

Okay. So you mentioned the SPA that you have in place with FDA. I know that was kind of predicated on the utilization of disease-free survival as a primary endpoint. What does your KOL feedback and some of the market research you've conducted suggest about the clinical meaningfulness of that endpoint specifically? I know you've presented some secondary endpoint data. We'll talk about that in a minute. But just on the topic of disease-free survival, how do docs think about that as kind of a surrogate of improvement?

Paul Peter Tak, CEO

Yeah, so it's important to keep in mind, A, who are the treating physicians of these patients, and B, what do patients and physicians want to achieve in a localized prostate cancer setting where patients receive radical treatment. So the treating physicians are urologists. And in our case, also the radiation oncologist, because patients have the choice between radical prostatectomy, surgery, or radiotherapy. The outcomes in terms of risk of recurrence are more or less comparable. So it's based on other considerations that patients may choose radiotherapy over radical prostatectomy. We focus on the patients who are already selected and self-selected to undergo radiotherapy. EBRT, and the goal is to eradicate the tumor. That translates in regulatory terms into an endpoint of disease-free survival, as we've seen in other indications like breast cancer, where medicines have been approved based on disease-free survival. However, it has not been used. Before in prostate cancer, that's why the SPA is so important. Why? Because there's no medicine that has delivered, actually, on the promise of really preventing recurrence in a localized prostate cancer setting. So the urologist and the radiation oncologist know that these patients want to accept the side effects and long-term complications of radiotherapy. Same is true for surgery. Why? Because they want to get rid of their cancer. They want to live free from cancer. They want to avoid the need for future toxic therapies like Selfridge ADT, long-term ADT, which has a very negative impact on quality of life in at least two-thirds of the patients. They want to avoid local progression of the disease and metastatic disease, which is associated with signs and symptoms. So urologists and radiation oncologists understand quite intuitively that more patients want to achieve this goal of living free from cancer, living free from cancer-related anxiety, and the symptoms due to local and metastatic progression of the disease, and the need for selfish anti-cancer therapies. And that's what we've achieved. Early on, we did already extensive market research, both in the U.S. and in Europe. With our partner, Global Life Sciences, that has shown both in radiation therapy and in urology, both in academia and the community center, that there was huge support for this approach, 100% of the respondents indicated that they would implement this in their clinical practice. And since then, we've done deeper research, especially with the advent of our chief commercial officer, Mark Sims, who is here in the room, who came from a leading role at AstraZeneca. We've started to work with FASANA. We've organized many SABs. We work very closely with the Prostate Cancer Foundation. So there's very strong support from the community. In terms of medical oncologists, these medical specialists typically do not treat early localized prostate cancer, right? They see the medical oncologist and they have advanced disease. So you always need to educate them and say, well, what is it actually that we try to achieve, right? We are not trying to achieve an advanced disease that patients live longer with cancer. We're trying to actually help them to live without cancer. And the upside, ultimately, after an additional 10 years, is that if you don't have cancer anymore, Or any evidence of recurrence, you will not die because of prostate cancer. So that's what we hear back during our SABs.

Stephen Willie, Analyst — Stifel

Okay. So DFS was the primary, a lot of the secondary endpoint data you presented at AUA back in May. I know I was pretty impressed with the delay in time to metastasis. I know in a lot of the KOL discussions we have had. They had really kind of prioritized that endpoint from kind of a clinical meaningfulness perspective. I guess in that time to metastasis data, though, right, there also appeared to be a little bit of a bifurcation between outcomes in intermediate and high-risk patients. And so how do you think about that secondary endpoint data informing potential labeling? When the primary endpoint of DFS would suggest there's not a bifurcation between the risk subgroups.

Paul Peter Tak, CEO

Interesting question. So first, we have achieved our primary endpoint in December 2024, which was the CH3 survival, supported by secondary endpoints like patients achieving a PSA nadir of less than 0.2 nanogram per mil. Other endpoints, explore the endpoints, that's key actually, was a two-year biopsy that's not part of standard of care, but it was done per protocol. So why is it not part of standard of care? Because it's not very pleasant to undergo an invasive prostate procedure. But it is the gold standard and the most sensitive way to detect cancer. And the physicians that we spoke to really like this, because in the most objective and sensitive way, this is the gold standard to demonstrate human cells. We've shown elimination of human cells in more patients who have achieved aglatimogen versus placebo. Then there's data in the literature, including a meta-analysis based on 22 clinical trials, that shows the association between seeing tumor cells in a two-year biopsy after radiotherapy with curative intent for localized prostate cancer, and after extended follow-up, subsequent biochemical failure and subsequent development of metastases, and even after longer follow-up. So, in December 2024, when we had seen the data, that we had like more than 80%, I think it was 80.6% of the patients achieving a negative biopsy in the acletymogen group, statistically more than in the control group, we predicted that if we would continue to follow these patients, we would start to see a separation for biochemical failure and time to metastases and a time to salvage anti-cancer therapy. So this was not part of the secondary endpoint. This is an exploratory endpoint that was not requested by the FDA. But this is exactly what we are starting to see. This was accepted for a plenary oral session at the American Neurology Association meeting, AUA meeting. And this resonates with physicians who are maybe not used to research tools like prostate biopsies at two years and who will just test the PSA levels in the blood of their patients. So they see that, oh, this is something we recognize in the clinic. To your point, is there a difference between intermediate risk versus high risk? I think we need to be careful because the numbers of events get really small in the high risk group, right? Again, 85% of our patients in the trial had intermediate risk prostate cancer. So I think we do show the analysis in our slide deck that's online on our website for the overall population. Then we also showed analysis, because it's still about 650 patients, for the intermediate risk group. But if you look at the high-risk group, the number of events is really small, because it's a small number of patients. So I think it's very difficult to draw conclusions. There's no reason to believe that biology would be different from high-risk versus intermediate-risk prostate cancer. It's also not that we've seen for the primary and secondary endpoints. And I should also highlight that our high-risk population is a special high-risk population because they could not have more than a single high-risk factor. So it's relatively low-risk, high-risk prostate cancer, if you can still follow me. So we believe it will be a continuum. And the final point is the high-risk prostate cancer more often used ADT, right, because that's recommended due to the guidelines, which may mask actually the efficacy of other treatments like Arglatimidium. We've seen the same in other fields like OT immunity. We know that there were big phase three trials that could not demonstrate the efficacy of, let's say, rituximab in systemic lupus because all the patients got 60 milligrams of prednisolone, right? So you mask the effect. Of course, you want to get rid of prednisolone in that setting as you want to get rid of ADT in the prostate cancer setting.

Stephen Willie, Analyst — Stifel

Okay. You talked about the desire that exists from a physician perspective to implement this into clinical practice. Can you maybe just speak to the logistical part of the equation? Obviously, this is kind of three separate injections. It's spaced over the course of a couple of months. It's going to be administered in community urology practices. It's going to be administered by radiologists. What does your outreach tell you just about the logistics of incorporating this in the clinical practice?

Paul Peter Tak, CEO

So it's always very good to think through what this means in terms of work streams and in clinical practice. And here, again, I want to highlight that the treating physicians are urologists and radiation oncologists, and they work already together because in this setting, the urologists have actually referred the patient to a radiation oncologist to get radiotherapy. And this is quite attractive for these treating physicians because they are doing procedures anyway, right? As I mentioned, I mean, urologists do very complicated procedures like robotic radical prostatectomy. So the prostate biopsy is a very simple procedure in their hands. And this is much simpler and less invasive than the prostate biopsy. So this is for them extremely easy. But the same is true for radiation oncologists who also do procedures in the prostate, They'd like the placement of fiducials or spacers. So they're used to doing this. So the collaboration between urologists and radiation oncologists exists already in multidisciplinary teams, both in community centers and in academia. And they're also used to do these procedures. They are very much aware of the fact that patients undergo procedures with quite a lot of downsides in terms of side effects. Think of urinary incontinence, think of erectile dysfunction, loss of quality of life. They do that because they want to live without cancer. So for radiation oncologists, it will be very attractive that they see improved outcomes of their patients. It's attractive for urologists because they will still play a role. We believe that after approval, hoping that we get to that point, that the urologist in most cases will actually do the procedure. There will be a reimbursable procedure. There will be a commercial incentive to prescribe our medicine. So it's very much aligned with normal clinical practice.

Stephen Willie, Analyst — Stifel

The reimbursable procedure, does that manifest in the form of a separate J-code that is not coupled to the product itself?

Paul Peter Tak, CEO

Yeah, we believe there will be a reimbursement for both the procedure and for the medicine.

Stephen Willie, Analyst — Stifel

And then maybe you can talk a little bit about the work that you've done on the reimbursement side, engaging payers, and maybe how that has informed your current thoughts around what a price point might look like.

Paul Peter Tak, CEO

Yes, certainly. So we've done work from the early days since I joined this company six years ago, a little bit more, with Global Life Sciences that did initial market research and pay research, both in the U.S. and in Europe, where there was real interest in our program. But more recently, we've done deeper research, especially with the advent of our chief commercial officer, as I mentioned, and our collaboration with EFASANA that has a global footprint. They did much deeper payer research. And to our surprise, although we had initially modeled that this would be a blockbuster indication, it's a very big indication, actually, larger than non-sponsored lung cancer, That initially, Globe Life Sciences had used very conservative assumptions for price. So if you look at the price range for GU tumors, especially including patients treated during earlier stages of the disease, right, with curative intent, then probably the price is much higher than we initially modeled. The median price range is $285,000. In our case, that would be for three administrations. I don't say that we get this price. We are doing the additional payer research. You always need to be careful. You need to negotiate this. But we believe that this will sit in the range that we will update very shortly. But again, the median, there is 285,000 for three administrations in our case. What payers really like when we talk to them in the U.S. is that, A, we have achieved the primary endpoints supported by relevant secondary and exploratory endpoints, as we discussed. Also, the work that I mentioned, the extended follow-up data at AUA, are maybe more for the payers, actually, than for the regulators. The regulators did not request these data, but this shows the relevance. The second point is... We have not shown any increase in serious adverse events after aglatimidine versus placebo, so it's always about benefit-risk that payers focus on. And the third point that I really liked is that... It's not a recurring cost to the healthcare system, right? So you give a bond of treatment, albeit consisting of three courses, and off they go, and that's it. Probably also trying to avoid future costs to the healthcare system, like the need for long-term ADT, which brings a significant cost, and toxicity and loss of quality of life. And we started to see that in the AUA data.

Stephen Willie, Analyst — Stifel

Maybe we can spend the last few minutes on lung cancer. You also have a phase three registrational effort that you just started a few months ago. This is in. Second-line non-small cell lung cancer, you are trying to defeat that which has not been defeated by the drug development industry to date, which is docetaxel as a second-line comparator. So as you think about the lung data that you've seen with that glatimogene in phase two, what gives you confidence that you're going to be able to take down docetaxel where so many others have been?

Paul Peter Tak, CEO

Yeah, everything always fails until somebody figures out how to develop a medicine that works, right? And it should all be based on the data. So our data were recently published in the Journal of Immunotherapy of Cancer, clinical data supported by deep immunological biomarker data. We focus on the patient cohort with very unfavorable baseline prognostic factors. And the data are in the paper, and also you can find it on our corporate slide deck, right? Many, 90% of these patients had failed immune checkpoint inhibitors, most of them also chemotherapy, sometimes multiple lines of chemotherapy. 90% had stage 4 disease or metastatic disease, in most cases progressing, despite optimal standard of care. Many of them were current or past smokers. More than 50% had very low or undetectable PD-L1 expression. So it's a really bad group, right? And typically, these patients get docetaxel, second-line chemotherapy, as you mentioned, which is consistently associated with the median overall survival of less than one year. So in the group that received two administrations of aglatimogen and the second administration is critical because this works like a vaccine. We turn the tumor into a vaccine, basically, in the patient. We teach the patient's own immune cells how to recognize these cancer antigens. So here we could show that in these patients who had an inadequate response to optimal standard of care, it's a treatment that's well-tolerated, generally speaking. And that only comprises two administrations delivered during bronchoscopy. Bronchoscopy. So again, it's aligned with normal clinical practice where pulmonary physicians use bronchoscopes every day as their standard tool in clinical practice. So these data are encouraging, all supported by deep immunological biomarker data. So that gives us quite a lot of confidence. And now we want to replicate this in phase three. There are always learnings from a clinical trial. So we have learned that in non-squamous, it looks even better than in squamous. It looks even better if you inject a lesion in the thorax rather than, let's say, in the liver. So we've made a change there. And you need to make sure that you are not misled by a CT scan at six weeks, because there may be pseudoprogression. We replaced tumor cells by immune cells. So these lessons have all been implemented in the protocol for the phase three. So we hope to replicate and maybe even improve on the data that we published based on the phase two study.

Stephen Willie, Analyst — Stifel

I know we're kind of out of time here, but anything we didn't cover that you would like to quickly highlight before we wrap things up?

Paul Peter Tak, CEO

Very briefly, I think this is a pan-solid tumor approach with a lot of opportunities. It's a real platform. I also want to highlight that Lino-Sypatri, our second investigational medicine, has very exciting data. We speak a lot about aglotymedia because it's in a late stage of development. But there again, we make very good progress. And there's also an opportunity to expand into other indications outside the brain.

Stephen Willie, Analyst — Stifel

Okay. There's a 60% chance I skipped that. Last one, because I'm still struggling, trying to figure out how to pronounce it.

Paul Peter Tak, CEO

Ken 3110. Thank you very much. Thank you, Paul-Peter. Thank you very much.